Skip to main content

Advertisement

SpringerLink
Log in

Blood Pressure Goals and Targets in the Elderly

  • Prevention (L Sperling and D Gaita, Section Editors)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

The American College of Cardiology (ACC)/American Heart Association (AHA) 2011 expert consensus document on hypertension in the elderly recommends that the blood pressure be reduced to less than 140/90 mmHg in adults aged 60–79 years and the systolic blood pressure to 140 to 145 mmHg if tolerated in adults aged 80 years and older. I strongly support these guidelines based on clinical trial data, especially from the Systolic Hypertension in the Elderly trial and from the Hypertension in the Very Elderly trial (HYVET). Other guidelines supporting reducing the blood pressure to less than 140/90 mmHg in adults aged 60 to 79 years of age include the European Society of Hypertension (ESH)/European Society of Cardiology (ESC) 2013 guidelines, the minority report from the 2013 Eighth Joint National Committee (JNC 8) guidelines, the 2013 Canadian Hypertension Education Program guidelines, the 2011 UK guidelines, the 2014 American Society of Hypertension (ASH)/International Society of Hypertension (ISH) guidelines, and the 2015 AHA/ACC/ASH scientific statement on treatment of hypertension in patients with coronary artery disease. I support these guidelines. In adults aged 80 years and older, a blood pressure below 150/90 mm Hg has been recommended by these guidelines, with a target goal of less than 140/90 mmHg considered in those with diabetes mellitus or chronic kidney disease. I support these guidelines. The 2013 JNC 8 guidelines recommend reducing the blood pressure to less than 140/90 mmHg in adults aged 60 years and older with diabetes mellitus or chronic kidney disease but to less than 150/90 mmHg in adults aged 60 years and older without diabetes mellitus or chronic kidney disease. I strongly disagree with this recommendation and am very much concerned that the higher systolic blood pressure goal recommended by JNC 8 guidelines in adults aged 60 years and older without diabetes mellitus or chronic kidney disease will lead to an increase in cardiovascular events and mortality in these adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–114. These guidelines recommend that the systolic blood pressure be reduced to less than 140 mm Hg in adults aged 60–79 years and to 140 to 145 mm Hg if tolerated in adults aged 80 years and older.

    Article  PubMed  Google Scholar 

  2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181.

    Article  PubMed  Google Scholar 

  3. Aronow WS, Ahmed MI, Ekundayo OJ, et al. A propensity-matched study of the association of PAD with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol. 2009;103:130–5.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466–72.

    Article  CAS  PubMed  Google Scholar 

  5. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560–72.

    Article  CAS  PubMed  Google Scholar 

  6. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88.

    Article  PubMed  Google Scholar 

  7. Aronow WS. Hypertension guidelines. Hypertension. 2011;58:347–8.

    Article  PubMed  Google Scholar 

  8. Bangalore S, Qin J, Sloan S, et al. What is the optimal blood pressure in patients after acute coronary syndromes? relationship of blood pressure and cardiovascular events in the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142–51.

    Article  CAS  PubMed  Google Scholar 

  9. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.

    Article  PubMed Central  Google Scholar 

  11. Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes. Subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74–83.

    Article  PubMed  Google Scholar 

  12. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727–36.

    Article  PubMed  Google Scholar 

  13. Appel LJ, Wright Jr JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–29.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641–50.

    Article  CAS  PubMed  Google Scholar 

  15. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939–46.

    Article  PubMed  Google Scholar 

  16. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541–8.

    Article  PubMed  Google Scholar 

  17. Banach M, Bhatia V, Feller MA, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208–14.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Ovbiagele B, Diener H-C, Yusuf S, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011;306:2137–44.

    Article  CAS  PubMed  Google Scholar 

  19. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.

    Article  Google Scholar 

  20. Perry Jr HM, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465–71.

    Article  PubMed  Google Scholar 

  21. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212–6.

    Article  CAS  PubMed  Google Scholar 

  22. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Eng J Med. 2008;358:1887–98.

    Article  CAS  Google Scholar 

  23. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219. These guidelines recommend reducig the systolic blood pressure to less than 140 mm Hg in adults aged 60 to 79 years and in adults aged 80 years and older with a systolic blood pressure of 160 mm Hg or higher to between 140–150 mm Hg provided they are in good physical and mental conditions.

    Article  PubMed  Google Scholar 

  24. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20. These guidelines recommend reducing the systolic blood pressure in persons aged 60 years or older to less than 150 mm Hg if they do not have diabetes mellitus or chronic kidney disease and to less than 140 mm Hg if they have diabetes mellitus or chronic kidney disease.

    Article  CAS  PubMed  Google Scholar 

  25. Wright Jr JT, Fine LJ, Lackland DT, et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160:499–503. This minority report from JNC8 recommends that the systolic blood pressure goal in persons aged 60 to 79 years with hypertension without diabetes mellitus or chronic kidney disease should be reduced to less than 140 mm Hg.

    Article  PubMed  Google Scholar 

  26. Navar-Boggan AM, Pencina MJ, Williams K, et al. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311:1424–9.

    Article  CAS  PubMed  Google Scholar 

  27. Banach M, Bromfield S, Howard G, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. Int J Cardiol. 2014;176:219–26.

    Article  PubMed  Google Scholar 

  28. Bangalore S, Gong Y, Cooper-DeHoff RM, et al. 2014 Eighth Joint National Committee Panel recommendation for blood pressure targets revisited: results from the INVEST study. J Am Coll Cardiol. 2014;64:784–93.

    Article  PubMed  Google Scholar 

  29. Krakoff LR, Gillespie RL, Ferdinand KC, et al. 2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations. J Am Coll Cardiol. 2014;64:394–402. The Association of Black Cardiologists and the Working Group on Women’s Cardiovascular Health support a systolic blood pressure goal of less than 140 mm Hg in persons aged 60 to 79 years and of less than 150 mm Hg in debilitated or frail persons aged 80 years and older.

    Article  PubMed  Google Scholar 

  30. National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. London: National Institute for Health and Clinical Excellence; 2011. These guidelines recommend reducing the systolic blood pressure to less than 140 mm Hg in adults younger than 80 years.

    Google Scholar 

  31. Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013;29:528–42. These guidelines recommend decreasing the systolic blood pressure to less than 140 mm Hg in adults s younger than 80 years of age and to less than 150 mm Hg in adults aged 80 years and older.

    Article  PubMed  Google Scholar 

  32. Weber MA, Schiffrin EL White WB, et al. Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society of Hypertension. 2014;16:14–26. These guidelines recommend reducing the blood pressure to less than 140/90 mm Hg in adults aged 80 years and younger and to less than 150/90 mm Hg in adults older than 80 years unless these persons have diabetes mellitus or chronic kidney disease when a target goal of less than 140/90 mm Hg should be considered.

    Google Scholar 

  33. Rosendorff C, Lackland DT, Allison M, Aronow WS, et al. AHA/ACC/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015. doi:10.1161/CIR.0000000000000207. These guidelines recommend that the optimal blood pressure in adults with coronary artery disease is less than 140/90 mm Hg.

    PubMed  Google Scholar 

  34. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA. 1996;275:1590–7.

    Article  CAS  PubMed  Google Scholar 

  35. Cook NR, Cutler JA, Obarzanek E, et al. Long-term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885–8.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Chang HY, Hu YW, Yue CS, et al. Effect of potassium-enriched salt on cardiovascular mortality and medical expenses of elderly men. Am J Clin Nutr. 2006;83:1289–96.

    CAS  PubMed  Google Scholar 

  37. Karppanen H, Mervaala E. Prog Cardiovasc Dis. 2006;49:59–75.

    Article  CAS  PubMed  Google Scholar 

  38. Yang Q, Liu T, Kuklina EV, et al. Sodium and potassium intake and mortality among US adults: prospective data from the third national health and nutrition examination survey. Arch Intern Med. 2011;171:1183–91.

    Article  PubMed  Google Scholar 

  39. He FJ, Pombo-Rodrigues S, Macgregor GA. Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. BMJ Open. 2014;4, e004549. doi:10.1136/bmjopen-2013-004549.

    Article  PubMed Central  PubMed  Google Scholar 

  40. US Department of Health and Human Services and US Department of Agriculture. Dietary guidelines for Americans. 6th ed. Washington DC: US Government Printing Office; 2005. January, 2005.

    Google Scholar 

  41. Law MR, Morris JK, Wald NJ. Use of BP lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi:10.1136/bmj.b1665.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet. 2003;362:591–2.

    Article  PubMed  Google Scholar 

  43. Carlberg B, Samuelson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684–9.

    Article  CAS  PubMed  Google Scholar 

  44. Aronow WS. Current role of beta blockers in the treatment of hypertension. Expert Opin Pharmacother. 2010;11:2599–607.

    Article  CAS  PubMed  Google Scholar 

  45. Aronow WS. Multiple blood pressure medications and mortality among elderly individuals. JAMA. 2015;313:1362–3.

    Article  CAS  PubMed  Google Scholar 

  46. Benetos A, Labat C, Rossignol P, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study. JAMA Intern Med. 2014. doi:10.1001/jamainternmed. 8012.

    Google Scholar 

  47. Banach M, Aronow WS. Blood pressure J curve. Curr Hypertens Rep. 2012;14:556–66.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Chiong JR, Aronow WS, Khan IA, et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol. 2008;124:6–21.

    Article  PubMed  Google Scholar 

  49. ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361:1953–62.

    Article  Google Scholar 

  50. Bax L, Woittiez AJ, Kouwenberg HJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med. 2009;150:840–8.

    Article  PubMed  Google Scholar 

  51. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13–22.

    Article  CAS  PubMed  Google Scholar 

  52. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.

    Article  PubMed  Google Scholar 

  53. Myat A, Redwood SR, Quereshi AC, et al. Resistant hypertension. BMJ. 2012;345, e7473. doi:10.1136/bmj.e7473 (published 20 November 2012).

    Article  PubMed  Google Scholar 

  54. Pimenta E, Calhoun DA. Resistant hypertension. Incidence, prevalence, and prognosis. Circulation. 2012;125:1594–6.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Gandelman G, Aronow WS, Varma R. Prevalence of adequate blood pressure control in self-pay or medicare patients versus medicaid or private insurance patients with systemic hypertension followed in a university cardiology or general medicine clinic. Am J Cardiol. 2004;94:815–6.

    Article  PubMed  Google Scholar 

  56. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–45.

    Article  CAS  PubMed  Google Scholar 

  57. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.

    Article  Google Scholar 

  58. Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976–82.

    Article  CAS  PubMed  Google Scholar 

  59. Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denervation therapy for resistant hypertension. J Am Coll Cardiol. 2013;62:231–41.

    Article  PubMed  Google Scholar 

  60. Schlaich MP, Schmieder RE, Bakris G, et al. International expert consensus statement. Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031–45.

    Article  PubMed  Google Scholar 

  61. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:393–401.

    Article  Google Scholar 

  62. Bakris GL, Townsend RR, Liu M, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64:1071–8.

    Article  PubMed  Google Scholar 

  63. Bakris GL, Townsend RR, Flack JM, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65:1314–21.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Wilbert S. Aronow declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Cardiology Division, Department of Medicine, Westchester Medical Center/New York Medical College, Macy Pavilion, Room 138, Valhalla, NY, 10595, USA

    Wilbert S. Aronow MD FACC FAHA

Authors
  1. Wilbert S. Aronow MD FACC FAHA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wilbert S. Aronow MD FACC FAHA.

Additional information

This article is part of the Topical Collection on Prevention

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aronow, W.S. Blood Pressure Goals and Targets in the Elderly. Curr Treat Options Cardio Med 17, 33 (2015). https://doi.org/10.1007/s11936-015-0394-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-015-0394-x

Keywords

Search

Navigation